ATE354570T1 - 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten - Google Patents
5,6-diaryl-pyrazineamidderivate als cb1 antagonistenInfo
- Publication number
- ATE354570T1 ATE354570T1 AT02788143T AT02788143T ATE354570T1 AT E354570 T1 ATE354570 T1 AT E354570T1 AT 02788143 T AT02788143 T AT 02788143T AT 02788143 T AT02788143 T AT 02788143T AT E354570 T1 ATE354570 T1 AT E354570T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrazineamide
- diaryl
- antagonists
- derivatives
- pyrazineamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE354570T1 true ATE354570T1 (de) | 2007-03-15 |
Family
ID=20286429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02788143T ATE354570T1 (de) | 2001-12-19 | 2002-12-18 | 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten |
Country Status (25)
Country | Link |
---|---|
US (1) | US7342019B2 (de) |
EP (1) | EP1458690B1 (de) |
JP (1) | JP2005517655A (de) |
KR (1) | KR20040068286A (de) |
CN (1) | CN1620438A (de) |
AR (1) | AR038044A1 (de) |
AT (1) | ATE354570T1 (de) |
AU (1) | AU2002352425A1 (de) |
BR (1) | BR0214989A (de) |
CA (1) | CA2469786A1 (de) |
CO (1) | CO5590917A2 (de) |
DE (1) | DE60218340T2 (de) |
ES (1) | ES2280599T3 (de) |
HU (1) | HUP0402026A3 (de) |
IL (1) | IL162377A0 (de) |
IS (1) | IS7314A (de) |
MX (1) | MXPA04005990A (de) |
NO (1) | NO20043022L (de) |
NZ (1) | NZ533275A (de) |
PL (1) | PL369731A1 (de) |
RU (1) | RU2004116916A (de) |
SE (1) | SE0104330D0 (de) |
TW (1) | TW200410694A (de) |
WO (1) | WO2003051851A1 (de) |
ZA (1) | ZA200404805B (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
CA2527033A1 (en) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators |
GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
WO2005007628A1 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
EP1680116A1 (de) * | 2003-10-24 | 2006-07-19 | Solvay Pharmaceuticals GmbH | Kombinationsbehandlung von adipositas mit selektiven cb1-antagonisten und lipasehemmern |
GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
RU2007119315A (ru) | 2004-10-25 | 2008-11-27 | Зольвай Фармасьютиклз Гмбх (De) | Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний |
ATE435207T1 (de) | 2005-04-06 | 2009-07-15 | Hoffmann La Roche | Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten |
AR053712A1 (es) * | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
RU2454405C2 (ru) * | 2006-10-04 | 2012-06-27 | Ф.Хоффманн-Ля Рош Аг | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина |
WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
WO2008081204A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH458361A (de) | 1965-01-15 | 1968-06-30 | Eprova Ag | Verfahren zur Herstellung von Pyrazincarbonsäuren |
JPS5322529A (en) * | 1976-08-13 | 1978-03-02 | Nippon Soda Co Ltd | Dihydropyrazine derivative and its preparation |
EP0397859A4 (en) | 1987-11-12 | 1990-12-19 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
WO1992002513A1 (en) | 1990-08-06 | 1992-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds |
FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
-
2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
-
2002
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en active IP Right Grant
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Application Discontinuation
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 EP EP02788143A patent/EP1458690B1/de not_active Expired - Lifetime
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
-
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL162377A0 (en) | 2005-11-20 |
BR0214989A (pt) | 2004-12-14 |
PL369731A1 (en) | 2005-05-02 |
ZA200404805B (en) | 2005-08-15 |
SE0104330D0 (sv) | 2001-12-19 |
HUP0402026A3 (en) | 2005-08-29 |
RU2004116916A (ru) | 2005-11-10 |
NO20043022L (no) | 2004-07-15 |
JP2005517655A (ja) | 2005-06-16 |
AR038044A1 (es) | 2004-12-22 |
DE60218340D1 (de) | 2007-04-05 |
CO5590917A2 (es) | 2005-12-30 |
EP1458690A1 (de) | 2004-09-22 |
CA2469786A1 (en) | 2003-06-26 |
IS7314A (is) | 2004-06-16 |
WO2003051851A1 (en) | 2003-06-26 |
US20050032808A1 (en) | 2005-02-10 |
HUP0402026A2 (hu) | 2005-02-28 |
CN1620438A (zh) | 2005-05-25 |
ES2280599T3 (es) | 2007-09-16 |
TW200410694A (en) | 2004-07-01 |
AU2002352425A1 (en) | 2003-06-30 |
EP1458690B1 (de) | 2007-02-21 |
KR20040068286A (ko) | 2004-07-30 |
DE60218340T2 (de) | 2007-11-29 |
MXPA04005990A (es) | 2004-09-27 |
NZ533275A (en) | 2006-02-24 |
US7342019B2 (en) | 2008-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60218340D1 (de) | 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten | |
DK1429761T3 (da) | Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning | |
DE60205100D1 (de) | DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN | |
NO20032892D0 (no) | 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning | |
DE60131971D1 (de) | 1,3,8-TRIAZA-SPIROi4,5 DECAN-4-ONDERIVATIVE ALS NEUROKININREZEPTORANTAGONISTEN | |
DE60019577D1 (de) | 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel | |
CY2014041I1 (el) | 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια | |
DE60214428D1 (de) | 1, 4-dihydro-1, 4-diphenylpyridin-derivate | |
DE60202761D1 (de) | Dihydro-benzo(b)(1,4)diazepin-2-on-derivate als mglur2 antagonisten | |
DE602004006169D1 (de) | Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate | |
NO20041075L (no) | Ny 1, 2, 4-triazolforbindelse | |
ATE370120T1 (de) | Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate | |
MXPA03006991A (es) | Derivados de piperidina como antagonistas de neurocinina 1. | |
DE60114852D1 (de) | Chinazolin-derivate als alpha-1 adrenerge antagonisten | |
DE60210598D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
DE50107988D1 (de) | Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate | |
ATE287405T1 (de) | 5-halogen-6-phenyl-7-fluoroalkylamino- triazolopyrimidine als fungizide | |
DE60214408D1 (de) | 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN | |
NO20042980L (no) | 3,4-dihydro-1H-isokinolin-2-yl-derivater | |
DE60210058D1 (de) | Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten | |
DE60201463D1 (de) | Indanon-Derivate als Duftstoffe | |
DE50206910D1 (de) | Substituierte y-lactonverbindungen als nmda-antagonisten | |
DE60315471D1 (de) | 2,5-disubstituierte 3-mercaptopentansaure | |
DE60213084D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
NO20044405L (no) | Neurotensinaktive 2,3-diaryl-pyrazolidin derivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |